ライフサイエンスコーパス: drug clearance

1 t is distinct from the role of metabolism in drug clearance.

2 cytochrome P450 enzyme activity and biliary drug clearance.

3 Adolescent and adult dosing information and drug clearance.

4 ding substrate binding in P450s that mediate drug clearance.

5 rculating anti-Neu5Gc antibodies can promote drug clearance.

6 of xenobiotic processing genes, and enhanced drug clearance.

7 s effective in patients with higher rates of drug clearance.

8 with broad specificity and implications for drug clearance.

9 ations returned to baseline values following drug clearance.

10 d that it inhibits SXR-mediated induction of drug clearance.

11 esented only a small portion of total parent drug clearance.

12 /kg, assessing elimination rates and time of drug clearance.

13 ted SXR and enhanced P-glycoprotein-mediated drug clearance.

14 ivities of SXR can be manipulated to control drug clearance.

15 h anticonvulsants and dexamethasone enhances drug clearance.

16 exposure to the drugs in patients with fast drug clearance.

17 ccount known relations between body mass and drug clearance.

18 d between-child physiological variability on drug clearance.

19 lected polymorphisms associated with reduced drug clearance adjusted for body mass index and the comp

20 mphatic systems contributes significantly to drug clearance after periocular injection; (3) corneal p

21 (CYPs) are a major enzymatic determinant of drug clearance and drug-drug interactions.

22 plications for the role of SXR in regulating drug clearance and hepatic disorders associated with imp

23 atic metabolism for preclinical screening of drug clearance and hepatotoxicity.

24 d interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.

25 localization, and function, thereby reducing drug clearance and increasing chemotherapy toxicity.

26 Induced neocapillaries increase drug clearance and limit tissue retention and subsequent

27 drug tolerance become counter-adaptive after drug clearance and result in symptoms of dependence.

28 f DXME in cancer cells significantly affects drug clearance and the onset of drug resistance.

29 es the role of transport proteins in hepatic drug clearance and toxicity, and addresses the increasin

30 lyte disorders, insulin resistance, impaired drug clearance, and mild coagulopathy.

31 ymes in cholesterol homeostasis and systemic drug clearance, and reveal novel regulatory pathways of

32 solubility and oral absorption, reduce free drug clearance, and selectively increase mTOR potency.

33 Adult and adolescent dosing and drug clearance data were obtained from FDA-approved drug

34 Pharmacokinetic analysis suggests that drug clearance from the CSF is biphasic, with a terminal

35 , the pharmacokinetic parameters and urinary drug clearance in C. apella primates are remarkably simi

36 Drug clearance in children younger than 12 years is fast

37 The mean time to drug clearance in infants was 4.0 months for adalimumab

38 with previous clinical reports of increased drug clearance in patients with untreated diabetes.

39 nuclear receptor SXR coordinately regulates drug clearance in response to a wide variety of xenobiot

40 of allometric scaling for the prediction of drug clearance in the adolescent population.

41 rophage depletion on tracer localization and drug clearance in vivo.

42 For most drugs, clearance increases nonlinearly with total body w

43 re should be avoided for up to 1 year unless drug clearance is documented, and pregnant women should

44 tensity and age for all adjusted agents, and drug clearance of doxorubicin and free etoposide was als

45 unger patients, and compensate for increased drug clearance over time.

46 Induction of a distinct drug clearance program by a high-affinity ligand for the

47 there is also the necessity to determine the drug-clearance properties of the polymorphic P450 enzyme

48 rate a remarkable ability to predict in vivo drug clearance rates of both rapid and slow clearing dru

49 high viral load and elevated antiretroviral drug clearance rates, which pose significant therapeutic

50 absorption and distribution and in enhancing drug clearance, respectively.

51 the following liver transporters involved in drug clearance: SLC10A1, SLC22A1, SLC22A7, SLC47A1, SLCO

52 Body-surface area did not correlate with drug clearance; therefore, fixed daily dosing of 25 mg/d

53 ntrast, CED of free CPT-11 resulted in rapid drug clearance (tissue t(1/2) = 0.3 day).

54 use model, for which a strong correlation of drug clearance to humans has been demonstrated.

55 d included studies if they contained data on drug clearance, volume of distribution, or drug concentr

56 endent in both nonhuman primates and humans; drug clearance was independent of dose but was higher in

57 Drug clearance was nonrenal and was not related to body-

58 Adolescent drug clearance was predicted from adult pharmacokinetic

59 A rodent study of drug clearance with [(14)C]-acetaminophen was performed

60 Allometric scaling predicted adolescent drug clearance with an overall mean absolute percentage

61 repeated JAKi treatment continued even after drug clearance, with persistent changes in chromatin acc